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PORTAL vein diversion has been used for many years to 
stop or prevent hemorrhage from esophageal varices or, 
less commonly, to treat intractable ascites. Since both the 
bleeding and ascites formation are due, at least in part, to 
blockage of the splanchnic venous return at or near the 
liver, the objective has been purely hemodynamic: relieve 
the obstruction, and the resulting portal venous hyperten-
sion will also be relieved. 
Within the last few years, a new dimension has been 
added to the old operation of portacaval shunt by employ-
ing this procedure to favorably alter the course of patients 
with two inborn errors of metabolism, glycogen storage 
disease, and type II hyperlipoproteinemia. We will discuss 
the potential postoperative risks borne by patients sub-
mitted to portal diversion for these new Indications and 
the probable mechanisms that explain the benefits of por-
tacaval shunt-these have been clarified by some recent 
advances in hepatic physiology. 
Glycogen Storage Disease 
The first portal diversion I for hepatic glycogen storage 
j" disease was performed more than 11 years ago in a girl who is still alive. By short-circuiting splanchnic venous 
. blood around the liver, it was hoped to make glucose more ~t: readily available to peripheral tissues, and thus to relieve 
hypoglycemia and coincidentally to deglycogenate the 
liver and palliate other metabolic derangements such as 
acidosis. In order to avoid the potential complication of he-
patic encephalopathy, which commonly follows portacaval 
shunt in dogs, the operation of portacaval transposition" 
was selected, whereby the bypassed portal flow is replaced 
with venous blood from the suprarenal inferior vena cava. 
Transposition was also performed by Riddell et al" of 
Bristol,England, in a boy who is still alive 91h years later. 
In that patient, the caval-to-portal venous anastomosis 
clotted' so that the liver was not provided with replace-
ment flow as was intended. After a second patient of ours 
died from complications of the transposition,' the simpler 
and technically safer operation of end-ta-side portacaval 
shunt was used in all seven subsequent cases at our cen-
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ter' and in all cases described elsewhere. Our seven surviv-
ors with end-ta-side portacaval shunt have been followed 
up for periods of from one to three years. 
The specific enzyme deficiencies in the Colorado cases' 
were of glucose-6-phosphatase (type I disease) in five pa-
tients, amyla-I-6-glucosidase (type III B) in three pa-
tients, and phosphorylase (type VI) in one patient. Preop- . 
eratively, all the children had retardation of growth, and 
all but the one with type VI disease had episodic hypogly-' 
cemia and acidosis. 
After portal diversion, the survivors had accelerated 
growth, and in all but one the height increase was in a 
spurt. The preexisting hypoglycemia was not relieved in 
some children but was variably improved in others. Liver 
size was either diminished or remained unchanged. In the 
latter event, the relative degree of hepatomegaly was 
steadily reduced as body growth occurred, When present, 
other metabolic abnormalities including secondary hyper-
lipemia, hyperuricemia, and platelet dysfunction were 
usually ameliorated. All other authors who have recorded 
their experience with portal diversion for glycogen stor-
age disease have also emphasized a high degree of pallia-
tion in their patients."'" 
Hyperlipemia 
In glycogen storage disease the liver is usually pat-
ently abnormal mainly because of the accumulation of 
glycogen, but also because of ·fibrosis, which occurs in a 
surprisingly high percentage of cases.' By contrast, the 
liver in homozygous type II hyperlipoproteinemia, the 
other metabolic disease for which portacaval shunt has 
been performed, is morphologically normal. The explana-
tion for the elevated serum cholesterol and low-density 
lipoprotein levels in this autosomal, dominant-inherited 
disorder is by no means understood. 'Goldstein and Browne 
have suggested that there may be an absence of or defect 
in the cell surface receptor sites that normally bind and 
transport low-density lipoprotein cholesterol into the cell. 
Because cholesterol does not enter the cell, they suggest 
that there is an absence of the normal feedback suppres-
sion of cholesterol synthesis. 
Whatever its cause, the homozygous form of type II hy-
perlipoproteinemia has a shockingly poor prognosis if there 
is no good response to medical therapy. Lipid-rich deposits 
are laid down in widely separated, superficial and deep 




. Coronary arteriogram 16 months after portacaval shunt. Diffuse 
narrowing of coronary arteries seen in preoperative study had 
resolved except for three discrete areas of occlusive disease; 
note one (arrow). 
parts of the body, including blood vessels, in which prema-
ture atherosclerosis is the consequence. Cardiac valves are 
similarly affected, and aortic stenosis is particularly com-
mon. The patients usually die of cardiovascular complica-
tions before 20 years of age. 
In an effort to reduce the serum cholesterol and lipo-
protein levels, and with the informed consent of the child 
and her mother, we performed an end-to-side portacaval 
shunt on March 1, 1973, in an ll-year-old girl with 
homozygous. type II hyperlipoproteinemia that was re-
fractory to medical treatment.'" The patient had suffered 
a myocardial infarction about two months previously. Af-
ter surgery, the serum cholesterol values fell from about 
800 mg/loo ml to levels that were consistently below 400 
mg/loo ml. Unsightly xanthomas began to resorb from 
visible subcutaneous and tendinous locations. At the same 
time, attacks of the preexisting angina pectoris became 
less frequent and finally stopped."'·" 
The child had cardiac catheterization three months 
before, which was 16 months after the end-to-side porta-
caval shunt was performed." On the second occasion, 
there was good evidence that reversal of aortic stenosis 
had occurred, with a diminution of the aortic valve 
gradient from 56 to 10 mm Hg. The coronary arteries 
were also thought to be less diseased than before, al-
though three stenoses were still present (Figure). On Sept 
23, 1974, tlie girl died suddenly while coming home from 
school. 
At autopsy, 18% months after portacaval shunt, the 
most important findings were present in the cardio-
vascular system.'" The heart weighed 510 gm (normal, 200 
gm). There was a large left ventricular aneurysm, which 
was the result of the old myocardial infarction. The three 
coronary artery stenoses identified by angiography three 
months earlier were still present, but there were no throm-
boses or areas of fresh infarction. The aortic valve easily 
admitted the tip of a finger. Many arteries, as well as the 
aorta, had residual xanthomatous deposits. The right and 
left lungs weighed 415 and 340 gm, respectively; histologic 
findings consistent with the chronic right-sided heart fail-
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ure, from which she had suffered since the original myocar-
dial infarction, were prescnt. The conclusion was that 
death was caused by an acute cardiac arrhythmia related 
to the residual coronary artery disease or to the earlier 
myocardial infarction. 
The portaca\'al shunt was widely patent. The liver. 
which weighed 618 gm, was grossly normal, and microscop-
ically it was unchanged from the biopsy specimen that 
was obtained six months postoperatively.'· On light and 
electron microscopy, the most prominent findings were 
shrinkage of the hepatocyte size, depletion of rough endo-
plasmic reticulum, and the accumulation of intracytoplas-
mic lipid deposits. Hepatic function had not been changed 
by portacaval shunt, as judged by standard liver function 
tests. 
We have performed a portacaval shunt on a second pa-
tient with the same diagnosis. This 7-year-old girl had 
preoperative serum cholesterol values that, while she was 
on a very low cholesterol diet, averaged 997 ± 47 (SD) 
mg/loo ml. Six months after the shunt, the cholesterol 
level measured in the same laboratory was 600 mg/lOO ml 
(a 40% reduction), despite a relaxation of the diet. As in 
the first case, this child had aortic stenosis and angina 
pectoris; it is too early to say if these findings will . be 
ameliorated. 
Central Registry 
A plea has been made by Ahrens" that all patients with 
homozygous type II hyperlipemia who are treated by porta-
caval shunt be carefully studied and faithfully reported to 
it central registry~ In this way ,tlle-Iipid-Iowering qualities 
of portal diversion will be promptly confirmed or denied, 
and in addition, clinical investigations that will shed light 
on the reasons for the antilipemic effect of the operation 
should be possible. So far, we have heard of seven more 
similar cases treated with portacaval shunt within the 
last few months, but without enough details to warrant 
comment. 
At the present time, we believe that portacaval shunt 
for hyperlipemia should be restricted to the highly lethal 
homozygous type II variety and then only if medical man-
agement fails. The certain establishment of the diagnosis 
and the appropriate investigation of each case require 
that such patients be seen in institutions that have a so-
phisticated interest in lipid metabolism. It is hoped that 
the proper study of these cases will lead to information 
that can be applied to other forms of hyperlipemia and the 
resulting premature atherosclerosis. 
Mechanisms for Metabolic Change 
Publications from our laboratory for the past ten years 
that have been summarized recently"·" have shown 
that venous blood returning from the splanchnic organs 
has special liver-supporting qualities that are not provided 
by equal volumes of other kinds of venous or arterial blood 
and that can affect hepatic hypertrophy, hyperplasia, and 
basic function. These qualities have been ascribed mainly 
to the endogenous hormones, especially insulin, that are 
released by the splanchnic viscera and thus arrive at the 
liver in high physiologic concentrations. The importance 
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of such hormone effects on the liver probably assumes in-
creased pertinence in hepatic homeostasis because the 
richness in nutrients of the same portal blood presum-
ably contributes to important hormone-substrate inter-
relationships. 
With end-to-side portacaval shunt, both nutritional and 
hormonal substances are diverted extrahepatically and 
may have contributed to the desired postoperative effects, 
both in glycogen storage disease and in hyperlipemia. Re-
cent animal studies have demonstrated that hepatic cho-
lesterol synthesis is greatly and permanently depressed 
after portal diversion, thus probably explaining most of 
the lipid-lowering influence of this procedure.'s 
Other observations"" have suggested that an increased 
peripheral insulinemia after portacaval shunt may explain 
the accelerated growth of children with glycogen storage 
disease. Ahrens13 has speculated on further possibili-
ties and has suggested studies by which these hypotheses 
could be validated or repudiated. 
Potential Hazards 
Collectively, the special hormonal and nutritional ingre-
dients described in portal venous blood have been termed 
hepatQtrophic substances. Their diversion from the liver, 
as with a portacaval shunt, produces derangements in ei-
ther morphologic features or function of the liver; in ani-
mals this may become severe and life-threatening. The 
most serious complication, and one that remains a poten-
tial specter, is hepatic encephalopathy. In dogs, seizures, 
coma, and death occur regularly withi ll a few weeks after 
portacaval shunt, at the same time as the rough endoplas-
mic reticulum of the hepatocytes is' decreased in amount, 
undergoes noticeable dilatation, and is depleted of ribo-
somes. '" Other changes in the liver cells include deglyco-
genation and the widespread accumulation of lipid vacu-
oles in the cytoplasm. 
Fortunately, the human appears resistant to the toxic 
effects of portal diversion. This species difference has 
made it possible to consider portal diversion for its meta-
bolic effects in patients. Detectable clinical morbidity in-
volving the liver-brain axis has not been seen in our pa-
tients who have been followed up for as long as 11 years. 
. Nevertheless, the clinical applications accept a "trade-
off" of distinctly suboptimal conditions of liver perfusion 
in return for metabolic improvements that are derived 
from these suboptimal conditions. Realization of this fact 
will encourage a conservative and discriminating attitude 
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about the recommendation of portacaval shunt for meta-
bolic purposes. 
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